Key Record Dates Identifier: NCT03065387
Brief Title: Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

First Submitted : February 22, 2017
First Submitted that Met QC Criteria : February 24, 2017
First Posted : February 27, 2017

Last Update Submitted that Met QC Criteria : November 1, 2019
Last Update Posted : November 4, 2019